Ginkgo Bioworks Holdings (DNA) Debt Ratio (2020 - 2021)

Ginkgo Bioworks Holdings (DNA) posted Debt Ratio of 0.0 for Q2 2021, up 58.05% on a QoQ basis from 0.0 in Q4 2020.

Ginkgo Bioworks Holdings (DNA) Debt Ratio (2020 - 2021) Analysis & Trends

Ginkgo Bioworks Holdings' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q2 2021.

Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was 0.0 (changed N/A YoY) and the FY2020 annual result came in at 0.0, changed N/A from the prior year.
Debt Ratio was 0.0 for Q2 2021 at Ginkgo Bioworks Holdings, up from 0.0 in the prior quarter.
Across five years, Debt Ratio topped out at 0.0 in Q2 2021 and bottomed at 0.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Ginkgo Bioworks Holdings	517.16 Mn	373.30 Mn	16.38 Mn	-

Historic Data

Download Data

Date	Value
Jun 30, 2021	0.00
Dec 31, 2020	0.00